Stemming the tide of drug resistance in cancer

Drug-tolerant persisters, de novo mutations and pre-existing resistance are just some of the ways cancers evade the effects of anti-cancer drugs. Can new targets and new dosing strategies tackle evolutionary forces directly to delay the inevitable?

Search for this author in:

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 19, 221-223 (2020)

doi: 10.1038/d41573-020-00050-y

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.